Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CingulateCING -3.49%36 Debt-to-Equity is 0.39 as of Mar. 2026, which is 30% below its 10-year median of 0.56. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Cingulate ranks worse than 68.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cingulate's Debt-to-Equity or its related term are showing as below:
CING'
s Debt-to-Equity Range Over the Past 10 Years
Min: -37.54 Med: 0.56 Max: 70.52
Current: 0.39
During the past 7 years, the highest Debt-to-Equity Ratio of Cingulate was 70.52. The lowest was -37.54. And the median was 0.56.
CING's Debt-to-Equity is ranked worse than 68.94% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs CING: 0.39
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cingulate Debt-to-Equity Related Terms
Cingulate Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cingulate's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CING vs IMA, MCRB, PLRX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Cingulate's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cingulate Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cingulate's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cingulate's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cingulate (CING) has a Debt-to-Equity of 0.39 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cingulate and its competitors. This is 30% below median its historical median of 0.56. According to the industry distribution chart, Cingulate ranks #666 out of 966 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Cingulate's Debt-to-Equity too high?
Cingulate's current Debt-to-Equity of 0.39 is 30% below median its 10-year median of 0.56. The Biotechnology industry median Debt-to-Equity is 0.16. Cingulate's value of 0.39 is 143.8% above this industry median. Based on the distribution chart, Cingulate ranks #666 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Debt-to-Equity compare to IMA and MCRB?
According to the Biotechnology industry distribution chart, Cingulate ranks #666 out of 966 companies for Debt-to-Equity. This places Cingulate in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Cingulate's value of 0.39 is 143.8% above this benchmark. While the company's 10-year median is 0.56 vs. the industry median of 0.16, Cingulate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cingulate's current Debt-to-Equity of 0.39 is 143.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cingulate and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cingulate's current Debt-to-Equity is 0.39, which is 30% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Debt-to-Equity of 0.39. The current Debt-to-Equity is 0.39, which is 30% below median its 10-year median of 0.56 and 143.8% above the Biotechnology industry median of 0.16. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cingulate (CING), the current Debt-to-Equity is 0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score
Get the complete analysis for CING
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CING has been successfully added to your 
